Australian Dollar: Oversold conditions limit losses against US Dollar – UOB
United Overseas Bank (UOB) strategists Quek Ser Leang and Lee Sue Ann note that AUD/USD outperformed on Monday, closing near 0.6970 after a modest rebound. Intraday, they see scope for slight gains but expect the pair to stay capped below 0.6985. Over 1–3 weeks, they judge that downward momentum is slowing and a break above 0.6985 would signal that the previously eyed 0.6866 support is unlikely to be reached, though medium‑term risks remain skewed lower.
Australian Dollar rebound but risks linger
"24-HOUR VIEW: Yesterday, we expected AUD to “trade sideways between 0.6930 and 0.6975.” AUD then traded within a slightly narrower range of 0.6933/0.6974, closing 0.30% higher at 0.6972. The tentative increase in upward momentum is not sufficient to signal a sustained advance. Today, AUD is likely to edge higher, but it is likely to stay within a 0.6945/0.6985 range. In other words, AUD is unlikely to break clearly above 0.6985."
"1-3 WEEKS VIEW: In our most recent narrative from last Friday (02 Oct, spot at 0.6930), we highlighted that “while the weakness that started in the middle of last month remains intact, given the deeply oversold conditions, any further decline may fall short of the next major support at 0.6866.” Downward momentum is starting to slow, and a break above 0.6985 (no change in ‘strong resistance’ level) would indicate that 0.6866 is out of reach."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Spyre Therapeutics shares tumble due to $350 million stock offering
On October 6, Spyre Therapeutics (SYRE.O) shares fell 4.1% to $88.90 in pre-market trading after the company priced a $350 million follow-on offering. The biotechnology firm announced late Monday that it was issuing approximately 4.1 million shares at $85 per share, an 8.3% discount to its last closing price. The company plans to use the net proceeds to advance its programs in gastroenterology, rheumatology, and dermatology, as well as to move a new project—SPY072—into later-stage development for the chronic skin disease hidradenitis suppurativa, among other uses. Jefferies, TD Cowen, Leerink, and Stifel are acting as joint book-running managers for the offering. On September 30, Merck’s (MRK.N) tulisokibart achieved success in a dermatology clinical trial, after which SYRE shares climbed about 5%. Analysts noted that the trial data supports SYRE's experimental candidate targeting the same signaling pathway. Headquartered in Waltham, Massachusetts, SYRE had around 88.2 million shares outstanding prior to the offering. As of Monday’s close, the stock had risen 183% year-to-date. According to LSEG data, 16 of 17 analysts rate the stock a “strong buy” or “buy,” with one analyst rating it “hold.” The median price target is $123. (For the convenience of non-English speakers, Reuters provides automated translations of its reports. Automated translations may contain errors or lack necessary context; Reuters makes no guarantee regarding the accuracy of machine translations and provides them for readers’ convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation.)
BUZZ-AMD shares rise on plans to increase chip supply
October 6 — U.S. chipmaker Advanced Micro Devices (AMD.O) saw its shares rise 1.5% in pre-market trading, reaching $641.10. CEO Lisa Su stated that as AMD races to meet surging demand in the artificial intelligence sector, the company plans to significantly boost chip supply by 2027 (link). Su also noted that AMD is working closely with memory chip manufacturers to ensure sufficient supply; her remarks come ahead of her scheduled visit to South Korea later on Tuesday. At least two brokerage firms, including Citigroup, have raised their price targets for the stock, according to data compiled by LSEG. Out of 56 brokerages, 47 rate AMD as a “buy” or higher, and 9 rate it as “hold”; the median price target is $616, per LSEG data. As of yesterday’s close, the stock has gained over 100% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these texts and provides them solely for readers’ convenience. Reuters accepts no liability for any damages or losses arising from the use of automated translations.)
New York securities industry targets profits of 90 billions USD! Goldman Sachs (GS.US) breaks quarterly records three times, Wall Street bonuses to hit all-time high
Profits of the New York securities industry are expected to surpass 90 billions USD, exceeding last year’s record of 65.1 billions USD, with bonuses potentially reaching all-time highs; underwriting income has increased by 68%, contributing 26.3 billions USD to state finances.
Citigroup (C.US) accelerates promotion pace to counter private equity headhunting
Citi (C.US) is shortening the time required for investment banking analysts to be promoted to associates in order to attract and retain top talent in a highly competitive job market.
Crypto prices
More
